2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Terminated
3
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Conditions
Breast Neoplasms
5
Neoplasm Metastasis
3
Stomach Neoplasms
2
Melanoma
2
Advanced Solid Tumors
2
Urinary Bladder Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Adenocarcinoma of the Stomach
1
Interventions
pembrolizumab
157
Gemcitabine
140
Capecitabine
123
Paclitaxel
121
Fluorouracil
117
Oxaliplatin
110
Bevacizumab
106
Nivolumab
99
Docetaxel
98
Leucovorin
97
Cisplatin
90
Radiosurgery
88
Irinotecan
88
Carboplatin
86
Cyclophosphamide
72
Cetuximab
72
Magnetic Resonance Spectroscopy
68
Specimen Handling
60
Radiotherapy
60
Trastuzumab
59
Biopsy
59
Ipilimumab
53
Drug Therapy
51
Everolimus
48
Pemetrexed
46
Albumin-Bound Paclitaxel
45
130-nm albumin-bound paclitaxel
44
Doxorubicin
42
Fulvestrant
40
aldesleukin
37
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
tesetaxel
×
Clear all
NCT03326674
2021-07-30
CONTESSA
Odonate Therapeutics, Inc.
Phase 3
Terminated
685 enrolled
NCT03858972
2021-07-30
CONTESSA 2
Odonate Therapeutics, Inc.
Phase 2
Terminated
152 enrolled
NCT03952325
2021-07-30
CONTESSA TRIO
Odonate Therapeutics, Inc.
Phase 2
Terminated
294 enrolled